On July 2, Moderna rose 5.72% in regular trading, reaching $77.615 per share with turnover of $123 million. The stock continues to rally on multiple catalysts that have been building since late June.

On the news front, Moderna hosted a Science Day event on June 25, where it first disclosed its in vivo CAR-T project mRNA-6007, targeting B-cell mediated autoimmune diseases with plans to enter clinical trials next year. The company also showcased its tumor vaccine, cancer prevention vaccine, and AI-driven R&D platform pipelines, fueling market expectations for a valuation re-rating from a single-product vaccine maker to a platform biotechnology company. Additionally, its seasonal flu vaccine candidate mRNA-1010 received unanimous 9-0 support from the FDA Vaccines and Related Biological Products Advisory Committee, with a final regulatory decision expected by August 5. Encouraged by these developments, Piper Sandler raised its price target to $77 from $69 while maintaining an Overweight rating, and Jefferies lifted its target to $53 from $45 with a Hold rating.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)